HC Wainwright reissued their buy rating on shares of Edesa Biotech (NASDAQ:EDSA – Free Report) in a report released on Friday, Benzinga reports. The brokerage currently has a $21.00 price target on the stock.
Edesa Biotech Stock Up 2.6 %
Shares of Edesa Biotech stock opened at $4.39 on Friday. The business has a fifty day simple moving average of $4.44 and a two-hundred day simple moving average of $4.58. Edesa Biotech has a 1 year low of $2.46 and a 1 year high of $8.33.
Edesa Biotech (NASDAQ:EDSA – Get Free Report) last posted its quarterly earnings data on Friday, May 10th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.11. Sell-side analysts predict that Edesa Biotech will post -2 EPS for the current year.
About Edesa Biotech
Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.
Read More
- Five stocks we like better than Edesa Biotech
- How to Calculate Return on Investment (ROI)
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Market Cap Calculator: How to Calculate Market Cap
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to invest in marijuana stocks in 7 steps
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
